What are the efficacy and side effects of everolimus?

Everolimus (Everolimus) is an mTOR (mammalian target of rapamycin) inhibitor. It is a targeted drug and is mainly used to treat a variety of cancers and certain non-cancerous diseases.

Everolimus exerts anti-tumor effects by inhibiting the mTOR signaling pathway and interfering with the growth, proliferation and angiogenesis of tumor cells. This signaling pathway plays an important role in processes such as cell proliferation, angiogenesis, and immune regulation.

Everolimus is widely used in the treatment of malignant tumors such as kidney cancer, breast cancer, and neuroendocrine tumors. Clinical studies have shown that everolimus can significantly prolong the survival period of patients and improve survival rate.

For patients with kidney cancer, the combined use of everolimus with radiotherapy or chemotherapy can significantly improve the patient's survival rate. For patients with pancreatic endocrine tumors, everolimus can inhibit tumor progression and delay disease progression.

Everolimus, an immunosuppressant, can be used to reduce rejection after organ transplantation. By inhibiting the activation and proliferation of immune cells, everolimus helps reduce the incidence of rejection and improves the survival rate of transplanted organs.

Everolimus is also used to treat tuberous sclerosis-related renal angiomyolipoma and subependymal giant cell astrocytoma, among other diseases. In these diseases, everolimus reduces the growth and proliferation of diseased cells by inhibiting the mTOR signaling pathway, thereby improving patients' symptoms and quality of life.

The side effects of everolimus are diverse and involve multiple systems. Stomatitis is one of the most common side effects of everolimus, manifesting as inflammation, ulceration and pain of the oral mucosa. Patients can achieve relief by keeping their mouths clean and using mouthwash.

Since everolimus has an immunosuppressive effect, patients are prone to infections during use, including bacterial, viral and fungal infections. Therefore, patients need to closely monitor infection symptoms and use antibiotics and other drugs for treatment under the guidance of a doctor.

Everolimus may cause metabolic abnormalities such as hyperglycemia and hyperlipidemia. Patients need to regularly monitor blood sugar and blood lipid levels and adjust treatment plans under the guidance of a doctor.

Everolimus may inhibit the proliferation and differentiation of hematopoietic progenitor cells, leading to a decrease in white blood cell count, thereby weakening the patient's ability to fight infection. Therefore, patients need to closely monitor blood routine indicators and carry out necessary treatment under the guidance of a doctor.

Some patients may develop pulmonary toxicity after taking everolimus, manifesting as non-infectious pneumonia and other symptoms. This condition is rare, but if it occurs, it requires immediate medical attention.

Everolimus may also cause gastrointestinal and systemic symptoms such as diarrhea, loss of appetite, fatigue, and weakness. In addition, some patients may also experience allergic reactions such as rash, itching, and edema. For these side effects, patients need to undergo symptomatic treatment under the guidance of a doctor and closely monitor changes in their condition.

Everolimus is suitable for patients with specific types of cancers and diseases. Patients need to clarify their condition and medication indications before use. Everolimus should be used with caution or contraindicated in pregnant and lactating women and patients with severe liver and renal impairment. Patients need to regularly monitor their physical condition and side effects while taking everolimus, including blood routine, liver and kidney function, blood sugar, and blood lipids. Doctors will adjust treatment plans based on patient monitoring results to ensure the safety and effectiveness of medication.

Everolimus may interact with other drugs, affecting each other's efficacy and safety. Therefore, patients should inform their doctors about other drugs they are taking before using everolimus, and make adjustments under the guidance of their doctors.

The dose of everolimus should be individually adjusted based on factors such as the patient's weight, condition, and tolerance. Patients should strictly follow the doctor's instructions during medication and should not increase or decrease the dosage or stop medication on their own.

References:

https://www.spandidos-publications.com/10.3892/ijo.2021.5234